$CLVS 5000 prostate patients at minimum 30% penetration should give us 1500 * 8000 *1.5 = $18M from Rubraca sales in 6 weeks of Q2. This should put the total Q2 sales around $65M - $70M. 50% prostate market should give more than $80M in total sales for Q2. With reduced costs, it should be a good ER. I will continue to hold.